ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0590

Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0514

Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0112

Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0125

Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0282

Electronic Health Record-Based Calcium Pyrophosphate Deposition Disease Registry: A Feasibility Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0213

Electronic Medical Record Inbox Volume Association with Physician Gender, Physician Burnout, and the COVID-19 Pandemic at an Academic Rheumatology Center

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0050

Elucidating Androgen Effects on Osteoclast Precursor Populations and Osteoclastogenesis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0351

Empowering Lupus Communities: Evaluating a National Peer Support Program for Lupus Teen, Young Adult Patients and Their Families

Patient Education/Community Programs Poster – ARP

10:30AM-12:30PM: Abstract Number: 0482

Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0080

Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0322

Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0068

Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0247

Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0373

Enhancing Lupus Patient Education and Support at Kings County Hospital

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0146

Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions

Epidemiology & Public Health Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].